Enochian gets license for inhaled treatment tech

By The Science Advisory Board staff writers

June 21, 2021 -- Enochian BioSciences has acquired a license for technology that can potentially treat and prevent all variants of the coronavirus as well as influenza.

Developed by Dr. Serhat Gumrukçu, PhD, director of Seraph Research Institute, the inhaled drug tricks the viruses to trigger the cells they infect to commit suicide instead of becoming virus-making factories. Delivered via a nanoparticle, the drug either rapidly treats an infection or waits for a cell to become infected before attacking it. It's possible a single inhalation of the drug could both treat and protect against infection for relatively long periods of time, according to Enochian.

The firm is requesting a preinvestigational new drug meeting with the U.S. Food and Drug Administration (FDA) soon.

Financial details of the license were not disclosed.


Copyright © 2021 scienceboard.net


Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter